Activity of 2-Chlorodeoxyadenosine in Blood Cancer
Author Information
Author(s): R.A. Nagourney, S.S. Evans, J.C. Messenger, Y. Zhuang Sul, L.M. Weisenthall
Primary Institution: The Memorial Cancer Institute
Hypothesis
What is the activity spectrum of 2-Chlorodeoxyadenosine (2-CDA) in human hematologic neoplasms?
Conclusion
2-CDA shows activity in many human hematologic neoplasms except for multiple myeloma, which exhibits significant resistance.
Supporting Evidence
- 2-CDA has shown clinical activity in various hematologic neoplasms.
- Multiple myeloma specimens revealed significant resistance to 2-CDA.
- Cross resistance was observed between 2-CDA and nitrogen mustard.
Takeaway
This study looked at how well a drug called 2-CDA works against different blood cancers, finding it helps many but not those with multiple myeloma.
Methodology
The study used the Differential Staining Cytotoxicity (DiSC) assay to evaluate the activity of 2-CDA on tumor specimens from patients with various hematologic malignancies.
Limitations
The study's findings may not extend to clinical outcomes without further clinical trials, particularly for multiple myeloma.
Participant Demographics
Patients with a variety of hematologic malignancies.
Statistical Information
P-Value
p<0.01
Confidence Interval
95%
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website